Johnson & Johnson Presents Positive Phase 3 Results for Apalutamide in Prostate Cancer Treatment
Johnson & Johnson presented final results of phase 3 study Proteus, showing that treatment with apalutamide, an androgen receptor inhibitor, associated with androgen deprivation therapy (ADT), administered for six months before and after surgical intervention for prostate cancer, leads to significant improvement in main short-term and long-term clinical outcomes